Cargando…
“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
There is great interest in the application of ‘artificial intelligence’ (AI) to pharmacovigilance (PV). Although US FDA is broadly exploring the use of AI for PV, we focus on the application of AI to the processing and evaluation of Individual Case Safety Reports (ICSRs) submitted to the FDA Adverse...
Autores principales: | Ball, Robert, Dal Pan, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112277/ https://www.ncbi.nlm.nih.gov/pubmed/35579808 http://dx.doi.org/10.1007/s40264-022-01157-4 |
Ejemplares similares
-
Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015) -
French Pharmacovigilance Public System and COVID-19 Pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020) -
Artificial Intelligence and the Future of the Drug Safety Professional
por: Danysz, Karolina, et al.
Publicado: (2018) -
Computational Approaches for Pharmacovigilance Signal Detection: Toward Integrated and Semantically-Enriched Frameworks
por: Koutkias, Vassilis G., et al.
Publicado: (2015) -
Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
por: Shrestha, Sunil, et al.
Publicado: (2021)